Study protocol of a randomised clinical trial testing whether metacognitive training can improve insight and clinical outcomes in schizophrenia

Javier-David Lopez-Morinigo, Verónica González Ruiz-Ruano, Adela Sánchez Escribano Martínez, María Luisa Barrigón Estévez, Laura Mata-Iturralde, Laura Muñoz-Lorenzo, Sergio Sánchez-Alonso, Antonio Artés-Rodríguez, Anthony S David, Enrique Baca-García, Javier-David Lopez-Morinigo, Verónica González Ruiz-Ruano, Adela Sánchez Escribano Martínez, María Luisa Barrigón Estévez, Laura Mata-Iturralde, Laura Muñoz-Lorenzo, Sergio Sánchez-Alonso, Antonio Artés-Rodríguez, Anthony S David, Enrique Baca-García

Abstract

Background: Although insight in schizophrenia spectrum disorders (SSD) has been associated with positive outcomes, the effect size of previous treatments on insight has been relatively small to date. The metacognitive basis of insight suggests that metacognitive training (MCT) may improve insight and clinical outcomes in SSD, although this remains to be established.

Methods: This single-center, assessor-blind, parallel-group, randomised clinical trial (RCT) aims to investigate the efficacy of MCT for improving insight (primary outcome), including clinical and cognitive insight, which will be measured by the Schedule for Assessment of Insight (Expanded version) (SAI-E) and the Beck Cognitive Scale (BCIS), respectively, in (at least) n = 126 outpatients with SSD at three points in time: i) at baseline (T0); ii) after treatment (T1) and iii) at 1-year follow-up (T2). SSD patients receiving MCT and controls attending a non-intervention support group will be compared on insight level changes and several clinical and cognitive secondary outcomes at T1 and T2, whilst adjusting for baseline data. Ecological momentary assessment (EMA) will be piloted to assess functioning in a subsample of participants.

Discussion: To the best of our knowledge, this will be the first RCT testing the effect of group MCT on multiple insight dimensions (as primary outcome) in a sample of unselected patients with SSD, including several secondary outcomes of clinical relevance, namely symptom severity, functioning, which will also be evaluated with EMA, hospitalizations and suicidal behaviour.

Trial registration: ClinicalTrials.gov: NCT04104347. Date of registration: 26/09/2019 (Retrospectively registered).

Keywords: Ecological momentary assessment; Insight; Metacognitive training; Schizophrenia spectrum disorders.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study CONSORT chart. Estimated flow of participants over the trial period

References

    1. Morgan C, Lappin J, Heslin M, Donogehue K, Lomas B, Reininghaus U, et al. Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. Psychol Med. 2014;44(13):2713–2726. doi: 10.1017/S0033291714000282.
    1. Lysaker PH, Pattison ML, Leonhardt BL, Phelps S, Vohs JL. Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. World Psychiatry. 2018;17:12–23. doi: 10.1002/wps.20508.
    1. Pijnenborg GH, Van Donkersgoed RJ, David AS, Aleman A. Changes in insight during treatment for psychotic disorders: A meta-analysis. Schizophr Res. 2013;144(1–3):109–117. doi: 10.1016/j.schres.2012.11.018.
    1. Pijnenborg GH, Timmerman ME, Derks EM, Fleischhacker WW, Kahn RS, Aleman A. Different effects of antipsychotic drugs on insight in patients with first episode of schizophrenia. Data from the European First-Episode Schizophrenia Trial. Eur Neuropsychopharmacol. 2015;25(6):808–816. doi: 10.1016/j.euroneuro.2015.02.012.
    1. Cooke MA, Peters ER, Kuipers E, Kumari V. Disease, deficit or denial? Models of poor insight in psychosis. Acta Psychiatr Scand. 2005;112:4–17. doi: 10.1111/j.1600-0447.2005.00537.x.
    1. Cuesta MJ, Peralta V, Campos MS, Garcia-Jalon E. Can insight be predicted in first-episode psychosis patients? A longitudinal and hierarchical analysis of predictors in a drug-naïve sample. Schizophr Res. 2011;130:148–156. doi: 10.1016/j.schres.2011.04.032.
    1. Aleman A, Agrawal N, Morgan KD, David AS. Insight in psychosis and neuropsychological function: meta-analysis. Br J Psychiatry. 2006;189:204–212. doi: 10.1192/bjp.189.3.204.
    1. Flavell JH. Metacognition and cognitive monitoring: a new area of cognitive–developmental inquiry. Am Psychol. 1979;34:906–911. doi: 10.1037/0003-066X.34.10.906.
    1. Wells A, Purdon C. Metacognition and cognitive-behaviour therapy: A special issue. Clin Psychol Psychoter. 1999;6(2):71–72. doi: 10.1002/(SICI)1099-0879(199905)6:2<71::AID-CPP186>;2-G.
    1. Beck AT, Baruch E, Balter JM, Steer RA, Warman DM. A new instrument for measuring insight: the Beck Cognitive Insight Scale. Schizophr Res. 2004;68:319–329. doi: 10.1016/S0920-9964(03)00189-0.
    1. Dimaggio G, Lysaker PH. From Research to Treatment. 1. New York: Routledge; 2010. Metacognition and Severe Adult Mental Disorders.
    1. Nair A, Palmer EC, Aleman A, David AS. Relationship between cognition, clinical and cognitive insight in psychotic disorders: A review and meta-analysis. Schizophr Res. 2014;152:191–200. doi: 10.1016/j.schres.2013.11.033.
    1. Moritz S, Woodward TS. Metacognitive Training for schizophrenia patients (MCT): A pilot study on feasibility, treatment adherence, and subjective efficacy. German J Psychiatry. 2007;10(3):69–78.
    1. Moritz S, Andreou C, Schneider BC, Wittekind CE, Menon M, Balzan R, et al. Sowing the seeds of doubt: a narrative review on metacognitive training in schizophrenia. Clin Psychol Rev. 2014;34(4):358–366. doi: 10.1016/j.cpr.2014.04.004.
    1. Jiang J, Zhang L, Zhu Z, Li W, Li C. Metacognitive training for schizophrenia: a systematic review. Shanghai Arch Psychiatry. 2015;27:149–157.
    1. Eichner C, Berna F. Acceptance and Efficacy of Metacognitive Training (MCT) on Positive Symptoms and Delusions in Patients With Schizophrenia: A Meta-analysis Taking Into Account Important Moderators. Schizophr Bull. 2016;42:952–962. doi: 10.1093/schbul/sbv225.
    1. Liu Y-C, Tang C-C, Hung T-T, Psai T-C, Ling M-F. The Efficacy of Metacognitive Training for Delusions in Patients With Schizophrenia: A Meta-Analysis of Randomized Controlled Trials Informs Evidence Based Practice. Worldviews Evid-Based Nurs. 2018;15(2):130–139. doi: 10.1111/wvn.12282.
    1. Philipp R, Kriston L, Lanio J, Khüne F, Härter M, Moritz S, et al. Effectiveness of metacognitive interventions for mental disorders in adults—A systematic review and meta-analysis (METACOG) Clin Psychol Psychother. 2018;26(2):1–14.
    1. Van Oosterthout B, Smit F, Krabbendam L, Castelein S, Staring ABP, Van der Gaag M. Metacognitive training for schizophrenia spectrum patients: a meta-analysis on outcome studies. Psychol Med. 2016;46(1):47–57. doi: 10.1017/S0033291715001105.
    1. Vohs JL, Leonhardt BL, James AV, Francis MM, Breier A, Mehdiyoun N, et al. Metacognitive Reflection and Insight Therapy for Early Psychosis: A preliminary study of a novel integrative psychotherapy. Schizophr Res. 2018;195:428–433. doi: 10.1016/j.schres.2017.10.041.
    1. De Jong S, Van Donkersgoed RJM, Timmerman ME, Aan Het Rot M, Wunderink L, Arends J, et al. Metacognitive reflection and insight therapy (MERIT) for patients with schizophrenia. Psychol Med. 2019;49:303–313. doi: 10.1017/S0033291718000855.
    1. Pijnenborg GHM, de Vos AE, Timmerman ME, Van der Gaag M, Sportel BE, Arends J, et al. Social cognitive group treatment for impaired insight in psychosis: A multicenter randomized controlled trial. Schizophr Res. 2019;206:362–369. doi: 10.1016/j.schres.2018.10.018.
    1. David AS. Insight and psychosis. Br J Psychiatry. 1990;156:798–808. doi: 10.1192/bjp.156.6.798.
    1. Amador XF, David AS. Insight and Psychosis. Awareness of Illness in Schizophrenia and Related Disorders. 2nd ed. New York: Oxford University Press; 2004.
    1. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM. Assessment of insight in psychosis. Am J Psychiatry. 1993;150(6):873–879. doi: 10.1176/ajp.150.6.873.
    1. Kemp R, David AS. Insight and Compliance. In: Blackwell B, editor. Treatment Compliance and the Therapeutic Alliance in Serious Mental Illness. The Netherlands: Harwood Academic Publishers; 1997. pp. 61–86.
    1. Barrigón ML, Berrouiguet S, Carballo JJ, Bonal-Giménez C, Fernández-Navarro P, Pfang B, et al. User profiles of an electronic mental health tool for ecological momentary assessment: MEmind. Int J Methods Psychiatr Res. 2016;26:e1554. doi: 10.1002/mpr.1554.
    1. Berrouiguet S, Ramírez D, Barrigón ML, Moreno-Muñoz P, Carmona R, Baca-García E, et al. Combining Continuous Smartphone Native Sensors Data Capture and Unsupervised Data Mining Techniques for Behavioral Changes Detection: A Case Series of the Evidence-Based Behavior (eB2) Study. JMIR Mhealth Uhealth. 2018;6(12):e197. doi: 10.2196/mhealth.9472.
    1. Sheehan DV, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E, et al. The MINI International Neuropsychiatric Interview (MINI): The Development and Validation of a Structured Diagnostic Psychiatric Interview. J Clin Psychiatry. 1998;59(20):22–23.
    1. Wechsler D. The Wechsler Adult Intelligence Scale–Revised. New York: The Psychological Corporation; 1981.
    1. Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8(3):271–276. doi: 10.2466/pms.1958.8.3.271.
    1. Lopez-Morinigo Javier-David, Di Forti Marta, Ajnakina Olesja, Wiffen Benjamin D., Morgan Kevin, Doody Gillian A., Jones Peter B., Ayesa-Arriola Rosa, Canal-Rivero Manuel, Crespo-Facorro Benedicto, Murray Robin M., Dazzan Paola, Morgan Craig, Dutta Rina, David Anthony S. Insight and risk of suicidal behaviour in two first-episode psychosis cohorts: Effects of previous suicide attempts and depression. Schizophrenia Research. 2019;204:80–89. doi: 10.1016/j.schres.2018.09.016.
    1. Soriano-Barceló J, López-Moríñigo JD, Ramos-Ríos R, Rodríguez-Zanabria EA, David AS. Insight assessment in psychosis and psychopathological correlates: Validation of the Spanish version of the Schedule for Assessment of Insight – Expanded Version. Eur J Psychiat. 2016;30(1):55–65.
    1. Sanz M, Constable G, Lopez-Ibor I, Kemp R, David AS. A comparative study of insight scales and their relationship to psychopathological and clinical variables. Psychol Med. 1998;28(2):437–446. doi: 10.1017/S0033291797006296.
    1. Morgan KD, Dazzan P, Morgan C, Lappin J, Hutchison G, Suckling J, et al. Insight, grey matter and cognitive function in first-onset psychosis. Br J Psychiatry. 2010;197(2):141–148. doi: 10.1192/bjp.bp.109.070888.
    1. Gutiérrez-Zotes JA, Valero J, Cortés MJ, Labad A, Ochoa S, Ahuir M, et al. Spanish Adaptation of the Beck Cognitive Insight Scale (BCIS) for Schizophrenia. Actas Esp Psiquiatr. 2012;40(1):2–9.
    1. Ochoa S, López-Carrilero R, Barrigón ML, Pousa E, Barajas A, Lorente-Roviera E, et al. Randomized control trial to assess the efficacy of metacognitive training compared with a psychoeducational group in people with a recent-onset psychosis. Psychol Med. 2017;47(9):1573–1584. doi: 10.1017/S0033291716003421.
    1. Peralta V, Cuesta MJ. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res. 1994;53:31–40. doi: 10.1016/0165-1781(94)90093-0.
    1. Kay SR, Fiszbein K, Opler A. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi: 10.1093/schbul/13.2.261.
    1. Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D. Searching for a consensus five-factor model for the Positive and Negative Syndrome Scale for Schizophrenia. Schizophr Res. 2012;137(1–3):246–250. doi: 10.1016/j.schres.2012.01.031.
    1. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6:201–208. doi: 10.1016/0920-9964(92)90003-N.
    1. Endicott J, Spitzer R, Fleiss J, Cohen J. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766–771. doi: 10.1001/archpsyc.1976.01770060086012.
    1. World Health Organization (WHO) WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) 2010.
    1. Carlson J, Ochoa S, Haro JM, Escartín G, Ahuir M, Guitierrez-Sotez A, et al. Adaptation and validation of the quality-of-life scale: Satisfaction with Life Domains Scale by Baker and Intagliata. Compr Psychiatry. 2009;50(1):76–80. doi: 10.1016/j.comppsych.2008.05.008.
    1. Insel TR. Digital Phenotyping: Technology for a New Science of Behavior. JAMA. 2017;318:1215–1216. doi: 10.1001/jama.2017.11295.
    1. Singh SP, Cooper JE, Fisher HL, Tarrant CJ, Lloyd T, Banjo J, et al. Determining the Chronology and Components of Psychosis Onset: The Nottingham Onset Schedule. Schizophr Res. 2005;80(1):117–130. doi: 10.1016/j.schres.2005.04.018.
    1. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Shizophr Bull. 1982;8(3):470–484. doi: 10.1093/schbul/8.3.470.
    1. Brett-Jones J, Garety P, Hemsley D. Measuring delusional experiences: A method and its application. Br J Clin Psychol. 1987;26:257–265. doi: 10.1111/j.2044-8260.1987.tb01359.x.
    1. Corcoran R, Mercer G, Frith CD. Schizophrenia, symptomatology and social inference: investigating theory of mind in people with schizophrenia. Schizophr Res. 1995;17:5–13. doi: 10.1016/0920-9964(95)00024-G.
    1. Gil D, Fernández-Modamio M, Bengoechea R, Arrieta M. Adaptation of the Hinting Task theory of the mind test to Spanish. Rev Psiquiatr Salud Ment. 2012;5:79–88. doi: 10.1016/j.rpsm.2011.11.004.
    1. Baron-Cohen S, Wheelwright S, Jolliffe T. Is There a “Language of the Eyes”? Evidence from Normal Adults, and Adults with Autism or Asperger Syndrome. Vis Cogn. 1997;4(3):311–331. doi: 10.1080/713756761.
    1. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2. New York: Routledge Academic; 1988.
    1. Cox D. Regression models and life tables (with discussions) J R Stat Soc. 1972;34:187–220.
    1. Lysaker PH, Roe D, Yanos PT. Toward understanding the insight paradox: internalized stigma moderates the association between insight and social functioning, hope, and self-esteem among people with schizophrenia spectrum disorders. Schizophr Bull. 2007;33(1):192–199. doi: 10.1093/schbul/sbl016.
    1. National Institute for Health and Clinical Excellence (NICE) Clinical Guidance 178 Schizophrenia and psychosis. 2014.
    1. Drake RE, Gates C, Whitaker A, Cotton PG. Suicide among schizophrenics: a review. Compr Psychiatry. 1985;26(1):90–100. doi: 10.1016/0010-440X(85)90053-7.
    1. Restifo K, Harkavy-Friedman JM, Shrout PE. Suicidal behaviour in schizophrenia: a test of the demoralization hypothesis. J Nerv Ment Dis. 2009;197(3):147–153. doi: 10.1097/NMD.0b013e318199f452.
    1. Schizophrenia Commission . The Abandoned Illness: A Report by the Schizophrenia Commission. 2012.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere